Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis
| العنوان: | Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis |
|---|---|
| المؤلفون: | Vijani Somaratne, Mitali Chatterjee, Marcela Montes de Oca, Pegine B. Walrad, Dimitris Lagos, Nidhi S. Dey, Renu Wickremasinghe, Srija Moulik, Bimalka Seneviratne, Hiro Goto, Sujai Senarathna, Paul M. Kaye, Shalindra Ranasinghe, Nayani Madarasinghe, Luiza Campos Reis, Sarah Forrester |
| المصدر: | The Journal of Clinical Investigation |
| بيانات النشر: | American Society for Clinical Investigation, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Adult, Male, Sodium stibogluconate, medicine.medical_treatment, Immunology, Leishmania donovani, Leishmaniasis, Cutaneous, Parasite load, B7-H1 Antigen, Lesion, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Cutaneous leishmaniasis, medicine, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, 030304 developmental biology, Whole blood, Molecular pathology, 0303 health sciences, Infectious disease, biology, CD68, business.industry, Concise Communication, Leishmaniasis, General Medicine, Immunotherapy, Leishmania, biology.organism_classification, medicine.disease, 3. Good health, Antimony Sodium Gluconate, 030220 oncology & carcinogenesis, Antimonial, Parasitology, Female, medicine.symptom, business, medicine.drug |
| الوصف: | Cutaneous leishmaniasis (CL) is a chronic skin disease caused by Leishmania parasites and in Sri Lanka, CL is caused by L. donovani. Pentavalent antimonials (e.g. sodium stibogluconate; SSG) are first line drugs for CL, despite protracted and painful treatment regimens. Data from animal models indicate that the effectiveness of SSG requires drug-immune synergy, but mechanistic insight from patients is lacking. We studied whole blood and lesion transcriptomes from CL patients in Sri Lanka at presentation and during SSG treatment. In lesions, we identified differential expression of immune-related genes, including immune checkpoint molecules, after the onset of treatment whereas no differentially expressed genes were identified in whole blood. We confirmed reduced lesional PD-L1 and IDO1 protein expression on treatment in a second validation cohort, using digital spatial profiling and quantitative immunohistochemistry. Dual IHC-FISH revealed significantly higher expression of these immune checkpoint molecules on parasite-infected compared to non-infected lesional CD68+ monocytes / macrophages. Crucially, early reduction in PD-L1 but not IDO1 expression was predictive of rate of clinical cure and occurred in parallel with a reduction in parasite load. A multivariate cox proportional hazard model showed that patients with lower PD-L1 expression on treatment were more likely to cure earlier (HR= 4.88). Our data support a model whereby the initial anti-leishmanial activity of antimonial drugs alleviates checkpoint inhibition of T cell immunity, facilitating immune-drug synergism and clinical cure. Our findings demonstrate that PD-L1 expression can be used as an early predictor of clinical response to SSG treatment and support the use of PD-L1 inhibition as adjunct host directed therapy in Sri Lankan CL. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1558-8238 0021-9738 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db580da50412b23fac6ee64fe76bb0c9Test http://europepmc.org/articles/PMC8592550Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....db580da50412b23fac6ee64fe76bb0c9 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....db580da50412b23fac6ee64fe76bb0c9 873 3 unknown 872.850952148438 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....db580da50412b23fac6ee64fe76bb0c9&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Vijani+Somaratne%22">Vijani Somaratne</searchLink><br /><searchLink fieldCode="AR" term="%22Mitali+Chatterjee%22">Mitali Chatterjee</searchLink><br /><searchLink fieldCode="AR" term="%22Marcela+Montes+de+Oca%22">Marcela Montes de Oca</searchLink><br /><searchLink fieldCode="AR" term="%22Pegine+B%2E+Walrad%22">Pegine B. Walrad</searchLink><br /><searchLink fieldCode="AR" term="%22Dimitris+Lagos%22">Dimitris Lagos</searchLink><br /><searchLink fieldCode="AR" term="%22Nidhi+S%2E+Dey%22">Nidhi S. Dey</searchLink><br /><searchLink fieldCode="AR" term="%22Renu+Wickremasinghe%22">Renu Wickremasinghe</searchLink><br /><searchLink fieldCode="AR" term="%22Srija+Moulik%22">Srija Moulik</searchLink><br /><searchLink fieldCode="AR" term="%22Bimalka+Seneviratne%22">Bimalka Seneviratne</searchLink><br /><searchLink fieldCode="AR" term="%22Hiro+Goto%22">Hiro Goto</searchLink><br /><searchLink fieldCode="AR" term="%22Sujai+Senarathna%22">Sujai Senarathna</searchLink><br /><searchLink fieldCode="AR" term="%22Paul+M%2E+Kaye%22">Paul M. Kaye</searchLink><br /><searchLink fieldCode="AR" term="%22Shalindra+Ranasinghe%22">Shalindra Ranasinghe</searchLink><br /><searchLink fieldCode="AR" term="%22Nayani+Madarasinghe%22">Nayani Madarasinghe</searchLink><br /><searchLink fieldCode="AR" term="%22Luiza+Campos+Reis%22">Luiza Campos Reis</searchLink><br /><searchLink fieldCode="AR" term="%22Sarah+Forrester%22">Sarah Forrester</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => The Journal of Clinical Investigation ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => American Society for Clinical Investigation, 2021. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Sodium+stibogluconate%22">Sodium stibogluconate</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Ftreatment%22">medicine.medical_treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Immunology%22">Immunology</searchLink><br /><searchLink fieldCode="DE" term="%22Leishmania+donovani%22">Leishmania donovani</searchLink><br /><searchLink fieldCode="DE" term="%22Leishmaniasis%2C+Cutaneous%22">Leishmaniasis, Cutaneous</searchLink><br /><searchLink fieldCode="DE" term="%22Parasite+load%22">Parasite load</searchLink><br /><searchLink fieldCode="DE" term="%22B7-H1+Antigen%22">B7-H1 Antigen</searchLink><br /><searchLink fieldCode="DE" term="%22Lesion%22">Lesion</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Young+Adult%22">Young Adult</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Cutaneous+leishmaniasis%22">Cutaneous leishmaniasis</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Indoleamine-Pyrrole+2%2C3%2C-Dioxygenase%22">Indoleamine-Pyrrole 2,3,-Dioxygenase</searchLink><br /><searchLink fieldCode="DE" term="%22030304+developmental+biology%22">030304 developmental biology</searchLink><br /><searchLink fieldCode="DE" term="%22Whole+blood%22">Whole blood</searchLink><br /><searchLink fieldCode="DE" term="%22Molecular+pathology%22">Molecular pathology</searchLink><br /><searchLink fieldCode="DE" term="%220303+health+sciences%22">0303 health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Infectious+disease%22">Infectious disease</searchLink><br /><searchLink fieldCode="DE" term="%22biology%22">biology</searchLink><br /><searchLink fieldCode="DE" term="%22CD68%22">CD68</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Concise+Communication%22">Concise Communication</searchLink><br /><searchLink fieldCode="DE" term="%22Leishmaniasis%22">Leishmaniasis</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Leishmania%22">Leishmania</searchLink><br /><searchLink fieldCode="DE" term="%22biology%2Eorganism%5Fclassification%22">biology.organism_classification</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%223%2E+Good+health%22">3. Good health</searchLink><br /><searchLink fieldCode="DE" term="%22Antimony+Sodium+Gluconate%22">Antimony Sodium Gluconate</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22Antimonial%22">Antimonial</searchLink><br /><searchLink fieldCode="DE" term="%22Parasitology%22">Parasitology</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Esymptom%22">medicine.symptom</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edrug%22">medicine.drug</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Cutaneous leishmaniasis (CL) is a chronic skin disease caused by Leishmania parasites and in Sri Lanka, CL is caused by L. donovani. Pentavalent antimonials (e.g. sodium stibogluconate; SSG) are first line drugs for CL, despite protracted and painful treatment regimens. Data from animal models indicate that the effectiveness of SSG requires drug-immune synergy, but mechanistic insight from patients is lacking. We studied whole blood and lesion transcriptomes from CL patients in Sri Lanka at presentation and during SSG treatment. In lesions, we identified differential expression of immune-related genes, including immune checkpoint molecules, after the onset of treatment whereas no differentially expressed genes were identified in whole blood. We confirmed reduced lesional PD-L1 and IDO1 protein expression on treatment in a second validation cohort, using digital spatial profiling and quantitative immunohistochemistry. Dual IHC-FISH revealed significantly higher expression of these immune checkpoint molecules on parasite-infected compared to non-infected lesional CD68+ monocytes / macrophages. Crucially, early reduction in PD-L1 but not IDO1 expression was predictive of rate of clinical cure and occurred in parallel with a reduction in parasite load. A multivariate cox proportional hazard model showed that patients with lower PD-L1 expression on treatment were more likely to cure earlier (HR= 4.88). Our data support a model whereby the initial anti-leishmanial activity of antimonial drugs alleviates checkpoint inhibition of T cell immunity, facilitating immune-drug synergism and clinical cure. Our findings demonstrate that PD-L1 expression can be used as an early predictor of clinical response to SSG treatment and support the use of PD-L1 inhibition as adjunct host directed therapy in Sri Lankan CL. ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => application/pdf ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1558-8238<br />0021-9738 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db580da50412b23fac6ee64fe76bb0c9" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db580da50412b23fac6ee64fe76bb0c9</link><br /><link linkTarget="URL" linkTerm="http://europepmc.org/articles/PMC8592550" linkWindow="_blank">http://europepmc.org/articles/PMC8592550</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....db580da50412b23fac6ee64fe76bb0c9 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Adult
[Type] => general
)
[1] => Array
(
[SubjectFull] => Male
[Type] => general
)
[2] => Array
(
[SubjectFull] => Sodium stibogluconate
[Type] => general
)
[3] => Array
(
[SubjectFull] => medicine.medical_treatment
[Type] => general
)
[4] => Array
(
[SubjectFull] => Immunology
[Type] => general
)
[5] => Array
(
[SubjectFull] => Leishmania donovani
[Type] => general
)
[6] => Array
(
[SubjectFull] => Leishmaniasis, Cutaneous
[Type] => general
)
[7] => Array
(
[SubjectFull] => Parasite load
[Type] => general
)
[8] => Array
(
[SubjectFull] => B7-H1 Antigen
[Type] => general
)
[9] => Array
(
[SubjectFull] => Lesion
[Type] => general
)
[10] => Array
(
[SubjectFull] => 03 medical and health sciences
[Type] => general
)
[11] => Array
(
[SubjectFull] => Young Adult
[Type] => general
)
[12] => Array
(
[SubjectFull] => 0302 clinical medicine
[Type] => general
)
[13] => Array
(
[SubjectFull] => Cutaneous leishmaniasis
[Type] => general
)
[14] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[15] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[16] => Array
(
[SubjectFull] => Indoleamine-Pyrrole 2,3,-Dioxygenase
[Type] => general
)
[17] => Array
(
[SubjectFull] => 030304 developmental biology
[Type] => general
)
[18] => Array
(
[SubjectFull] => Whole blood
[Type] => general
)
[19] => Array
(
[SubjectFull] => Molecular pathology
[Type] => general
)
[20] => Array
(
[SubjectFull] => 0303 health sciences
[Type] => general
)
[21] => Array
(
[SubjectFull] => Infectious disease
[Type] => general
)
[22] => Array
(
[SubjectFull] => biology
[Type] => general
)
[23] => Array
(
[SubjectFull] => CD68
[Type] => general
)
[24] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[25] => Array
(
[SubjectFull] => Concise Communication
[Type] => general
)
[26] => Array
(
[SubjectFull] => Leishmaniasis
[Type] => general
)
[27] => Array
(
[SubjectFull] => General Medicine
[Type] => general
)
[28] => Array
(
[SubjectFull] => Immunotherapy
[Type] => general
)
[29] => Array
(
[SubjectFull] => Leishmania
[Type] => general
)
[30] => Array
(
[SubjectFull] => biology.organism_classification
[Type] => general
)
[31] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[32] => Array
(
[SubjectFull] => 3. Good health
[Type] => general
)
[33] => Array
(
[SubjectFull] => Antimony Sodium Gluconate
[Type] => general
)
[34] => Array
(
[SubjectFull] => 030220 oncology & carcinogenesis
[Type] => general
)
[35] => Array
(
[SubjectFull] => Antimonial
[Type] => general
)
[36] => Array
(
[SubjectFull] => Parasitology
[Type] => general
)
[37] => Array
(
[SubjectFull] => Female
[Type] => general
)
[38] => Array
(
[SubjectFull] => medicine.symptom
[Type] => general
)
[39] => Array
(
[SubjectFull] => business
[Type] => general
)
[40] => Array
(
[SubjectFull] => medicine.drug
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vijani Somaratne
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Mitali Chatterjee
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marcela Montes de Oca
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pegine B. Walrad
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Dimitris Lagos
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nidhi S. Dey
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Renu Wickremasinghe
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Srija Moulik
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bimalka Seneviratne
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hiro Goto
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sujai Senarathna
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paul M. Kaye
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shalindra Ranasinghe
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nayani Madarasinghe
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Luiza Campos Reis
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sarah Forrester
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 11
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 15588238
)
[1] => Array
(
[Type] => issn-print
[Value] => 00219738
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[3] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 131
)
[1] => Array
(
[Type] => issue
[Value] => 22
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => The Journal of Clinical Investigation
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |